CAJ | 학술논문

目的：对左奥硝唑治疗腹部厌氧菌感染的临床有效性、安全性及药物经济学进行探讨。方法：对山东省立医院2013年3月至2014年10月收治的经筛选符合需经验性抗厌氧菌治疗的腹部厌氧菌感染患者118例，随机分为观察组（ n＝57）和对照组（n＝61）。观察组给予左奥硝唑0．5 g静脉滴注2／日（每瓶0．5～1．0 h内滴完），5～10 d为一疗程；对照组给予奥硝唑，用药方法同观察组。观察并比较2组患者用药后的临床有效率、细菌清除率、不良反应发生率及成本－效果分析。结果：观察组临床有效率为87．72％，对照组为83．61％，2组比较，有效率差异无统计学意义（P＞0．05）；观察组细菌清除率为90．91％，对照组为91．67％，2组比较，细菌清除率差异无统计学意义（ P＞0．05）；观察组平均痊愈时间为6．66 d，平均退热时间为2．82 d，平均住院天数为12．18 d，对照组则相应为7．18、3．18、13．97 d，2组上述3个指标差异均无统计学意义（均P＞0．05）；观察组不良反应发生率低于对照组，2组比较差异无统计学意义（ P＞0．05），观察组未发现对照组的中枢神经系统不良反应如头晕、头痛等，2组均未发现新发及严重不良反应；观察组的住院成本及成本－效果与对照组比较更低，这一结论仍需进一步临床研究。结论：左奥硝唑用于腹部厌氧菌感染有效、安全，具有临床应用价值。
목적：대좌오초서치료복부염양균감염적림상유효성、안전성급약물경제학진행탐토。방법：대산동성립의원2013년3월지2014년10월수치적경사선부합수경험성항염양균치료적복부염양균감염환자118례，수궤분위관찰조（ n＝57）화대조조（n＝61）。관찰조급여좌오초서0．5 g정맥적주2／일（매병0．5～1．0 h내적완），5～10 d위일료정；대조조급여오초서，용약방법동관찰조。관찰병비교2조환자용약후적림상유효솔、세균청제솔、불량반응발생솔급성본－효과분석。결과：관찰조림상유효솔위87．72％，대조조위83．61％，2조비교，유효솔차이무통계학의의（P＞0．05）；관찰조세균청제솔위90．91％，대조조위91．67％，2조비교，세균청제솔차이무통계학의의（ P＞0．05）；관찰조평균전유시간위6．66 d，평균퇴열시간위2．82 d，평균주원천수위12．18 d，대조조칙상응위7．18、3．18、13．97 d，2조상술3개지표차이균무통계학의의（균P＞0．05）；관찰조불량반응발생솔저우대조조，2조비교차이무통계학의의（ P＞0．05），관찰조미발현대조조적중추신경계통불량반응여두훈、두통등，2조균미발현신발급엄중불량반응；관찰조적주원성본급성본－효과여대조조비교경저，저일결론잉수진일보림상연구。결론：좌오초서용우복부염양균감염유효、안전，구유림상응용개치。
OBJECTIVE:To evaluate the efficacy, safety and pharmacoeconomics of levornidazole in the treatment of abdominal anaerobic infection.METHODS:The patients with abdominal anaerobic infection admitted to Shandong Provincial Hospital from Mar.2013 to Oct.2014 were randomized to either observation group ( n =57 ) treated by levornidazole at a dose of 0.5 g twice daily for 5 to 10 days or control group ( n=61 ) treated by omidazole at a dose of 0.5 g twice daily for 5 to 10 days.The clinical efficacy, safety and cost-effectiveness and bacterial clearance rate of levornidazole in the treatment of abdominal anaerobic infection were recorded and compared between the two groups. RESULTS:The response rate in the observation group vs.control group was 83.61% vs.87.72%, showing no significant differences between the two groups ( P>0.05);The rate of bacterial clearance in the observation group vs. control group was 90.91% vs.91.67%, which also did not reach significant difference ( P>0.05 ) .The average healing time was 6.66 days in study group and 7.18 days in control group, the average fever clearance time was 2.82 days in observation group vs.3.18 days in control group, and the average hospitalization days were 12.18 days in observation group and 13.97 days in control group, with all three indicators showing no significant differences between two groups (P>0.05).The incidence of adverse drug reaction was lower in the observation group than in the control group yet the differences between the two groups were nonsignificant ( P>0.05 ) .The adverse drug reaction of central nervous system including dizzy and headache noted in the control group were unnoted in the observation group.Neither group showed serious adverse drug reaction.The hospitalization cost and the cost-effectiveness ratio were lower in the observation group than in the control group, and this result need to be verified in further clinical research. CONCLUSION:Levornidazole is safe and effective thus of clinical application value in the treatment of abdominal anaerobic infection.